299 related articles for article (PubMed ID: 34361811)
1. Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells.
Gambles MT; Li J; Wang J; Sborov D; Yang J; Kopeček J
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361811
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo.
Tommy Gambles M; Li J; Christopher Radford D; Sborov D; Shami P; Yang J; Kopeček J
J Control Release; 2022 Oct; 350():584-599. PubMed ID: 36037975
[TBL] [Abstract][Full Text] [Related]
3. Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptors.
Li J; Gambles MT; Jones B; Williams JA; Camp NJ; Shami PJ; Yang J; Kopeček J
Drug Deliv Transl Res; 2024 May; ():. PubMed ID: 38802679
[TBL] [Abstract][Full Text] [Related]
4. Drug-free macromolecular therapeutics: Impact of structure on induction of apoptosis in Raji B cells.
Zhang L; Fang Y; Yang J; Kopeček J
J Control Release; 2017 Oct; 263():139-150. PubMed ID: 28024916
[TBL] [Abstract][Full Text] [Related]
5. Drug-free macromolecular therapeutics exhibit amplified apoptosis in G2/M phase arrested cells.
Li L; Yang J; Wang J; Kopeček J
J Drug Target; 2019; 27(5-6):566-572. PubMed ID: 30198798
[TBL] [Abstract][Full Text] [Related]
6. Human Serum Albumin-Based Drug-Free Macromolecular Therapeutics: Apoptosis Induction by Coiled-Coil-Mediated Cross-Linking of CD20 Antigens on Lymphoma B Cell Surface.
Zhang L; Fang Y; Li L; Yang J; Radford DC; Kopeček J
Macromol Biosci; 2018 Nov; 18(11):e1800224. PubMed ID: 30259654
[TBL] [Abstract][Full Text] [Related]
7. Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.
Wang J; Li L; Yang J; Clair PM; Glenn MJ; Stephens DM; Radford DC; Kosak KM; Deininger MW; Shami PJ; Kopeček J
Nanomedicine; 2019 Feb; 16():217-225. PubMed ID: 30639670
[TBL] [Abstract][Full Text] [Related]
8. Exploration and Evaluation of Therapeutic Efficacy of Drug-Free Macromolecular Therapeutics in Collagen-Induced Rheumatoid Arthritis Mouse Model.
Wang J; Li Y; Li L; Yang J; Kopeček J
Macromol Biosci; 2020 May; 20(5):e1900445. PubMed ID: 32196951
[TBL] [Abstract][Full Text] [Related]
9. Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis.
Chu TW; Yang J; Zhang R; Sima M; Kopeček J
ACS Nano; 2014 Jan; 8(1):719-30. PubMed ID: 24308267
[TBL] [Abstract][Full Text] [Related]
10. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
11. Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
Li L; Yang J; Wang J; Kopeček J
ACS Nano; 2018 Apr; 12(4):3658-3670. PubMed ID: 29595951
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors.
Gambles MT; Sborov D; Shami P; Yang J; Kopeček J
Macromol Biosci; 2024 Mar; 24(3):e2300375. PubMed ID: 37838941
[TBL] [Abstract][Full Text] [Related]
14. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
[TBL] [Abstract][Full Text] [Related]
15. Biorecognition: A key to drug-free macromolecular therapeutics.
Yang J; Li L; Kopeček J
Biomaterials; 2019 Jan; 190-191():11-23. PubMed ID: 30391799
[TBL] [Abstract][Full Text] [Related]
16. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
17. FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma.
Zhang G; Guo C; Wang Y; Zhang X; Liu S; Qu W; Chen C; Yan L; Yang Z; Zhang Z; Jiang X; Chen X; Liu H; Lai Q; Wei X; Lu Y; Zhao S; Deng H; Wang Y; Yu L; Yu H; Wu Y; Su Z; Chen P; Ren Z; Yu M; Qu F; Luo Y; Gou L; Li Q; Huang Y; Ma F; Yang J
J Hematol Oncol; 2022 Dec; 15(1):177. PubMed ID: 36581954
[TBL] [Abstract][Full Text] [Related]
18. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
García-Guerrero E; Götz R; Doose S; Sauer M; Rodríguez-Gil A; Nerreter T; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Danhof S
Leukemia; 2021 Jan; 35(1):201-214. PubMed ID: 32350373
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
